生物活性
6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.
IC50 & Target
endogenous purines[1]
细胞效力(Cellular Effect)
Cell Line
Type
Value
Description
References
A549
IC50
47 μM
Compound: 6-mercaptopurine
Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay
Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
A549
IC50
47 μM
Compound: C2
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
A549
IC50
47 μM
Compound: C2
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
A549
IC50
49.3 μM
Compound: 6-mercaptopurine
Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay
Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
A549
IC50
49.4 μM
Compound: C2
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
ASPC1
IC50
2.45 μM
Compound: 6-MP
Cytotoxicity against human Aspc-1 cells by crystal violet staining
Cytotoxicity against human Aspc-1 cells by crystal violet staining
[PMID: 20930123]
B16
IC50
0.8 μg/mL
Compound: 6-MP
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
[PMID: 7807120]
C6
IC50
30.2 μg/mL
Compound: 6-MP
Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay
Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay
[PMID: 11087619]
CCRF-CEM
CC50
1 μM
Compound: 6MP
Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
[PMID: 21741130]
CCRF-CEM
IC50
1 μM
Compound: 6MP
Antiproliferative activity against human CCRF-CEM cells by MTT assay
Antiproliferative activity against human CCRF-CEM cells by MTT assay
[PMID: 17254669]
CCRF-SB
CC50
1.1 μM
Compound: 6MP
Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
[PMID: 21741130]
CCRF-SB
IC50
1 μM
Compound: 6MP
Antiproliferative activity against human CCRF-SB cells by MTT assay
Antiproliferative activity against human CCRF-SB cells by MTT assay
[PMID: 17254669]
CHO
ED50
50 μM
Compound: 6MP
Cytotoxicity against CHO cells
Cytotoxicity against CHO cells
[PMID: 23411915]
COLO357
IC50
6.12 μM
Compound: 6-MP
Cytotoxicity against human Colo-357 cells by crystal violet staining
Cytotoxicity against human Colo-357 cells by crystal violet staining
[PMID: 20930123]
DAN-G
IC50
4.06 μM
Compound: 6-MP
Cytotoxicity against human DAN-G cells by crystal violet staining
Cytotoxicity against human DAN-G cells by crystal violet staining
[PMID: 20930123]
DU-145
CC50
2 μM
Compound: 6MP
Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay
[PMID: 21741130]
DU-145
IC50
2 μM
Compound: 6MP
Antiproliferative activity against human DU145 cells by MTT assay
Antiproliferative activity against human DU145 cells by MTT assay
[PMID: 17254669]
Daudi
IC50
> 200 μM
Compound: 6-MP
Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
[PMID: 18467007]
HEK293
IC50
0.007 μM
Compound: 6-MP
Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method
Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method
[PMID: 10757708]
HEK293
IC50
0.007 μM
Compound: 6-MP
Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay
Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay
[PMID: 16643040]
HEK293
IC50
0.007 μM
Compound: 6-MP
Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay
Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay
[PMID: 16989528]
HEK293
IC50
0.007 μM
Compound: 6-MP
Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay
Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay
[PMID: 18442289]
HEK293
IC50
7.1 x 10-7 mg/mL
Compound: 6-mercaptopurine
Cytotoxicity against HEK293 cells by rapid colorimetric assay
Cytotoxicity against HEK293 cells by rapid colorimetric assay
[PMID: 19133758]
HEp-2
IC50
317.8 μM
Compound: 6-mercaptopurine
Cytotoxicity against human Hep2 cells at exponential phase of growth after 48 hrs by MTT assay
Cytotoxicity against human Hep2 cells at exponential phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
HEp-2
IC50
431 μM
Compound: 6-mercaptopurine
Cytotoxicity against human Hep2 cells at lag phase of growth after 48 hrs by MTT assay
Cytotoxicity against human Hep2 cells at lag phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
HT-29
IC50
0.87 μg/mL
Compound: 6-MP
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 7807120]
HT-29
IC50
> 200 μM
Compound: 6-MP
Antiproliferative activity against multidrug-resistant human HT-29 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
Antiproliferative activity against multidrug-resistant human HT-29 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
[PMID: 18467007]
HeLa
ED50
0.1 μg/mL
Compound: 6-Mercaptopurine
Cytostatic activity against human HeLa cells assessed as growth inhibition after 72 hrs by colorimetric method
Cytostatic activity against human HeLa cells assessed as growth inhibition after 72 hrs by colorimetric method
[PMID: 671455]
HeLa
ED50
0.1 μg/mL
Compound: 6-mercaptopurine
Cytostatic activity against human HeLa cells after 72 hrs by FCR-based colorimetric method
Cytostatic activity against human HeLa cells after 72 hrs by FCR-based colorimetric method
[PMID: 448680]
HeLa
ED50
0.1 μg/mL
Compound: 6-mercaptopurine
In vitro cytostatic activity against human HeLa cells assessed as cell growth after 72 hrs by colorimetric method
In vitro cytostatic activity against human HeLa cells assessed as cell growth after 72 hrs by colorimetric method
[PMID: 458800]
HeLa
IC50
2.9 μM
Compound: 6-mercaptopurine
Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
HeLa
IC50
2.9 μM
Compound: C2
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
HeLa
IC50
2.9 μM
Compound: C2
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
HeLa
IC50
4.1 μM
Compound: 6-mercaptopurine
Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
HeLa
IC50
4.1 μM
Compound: C2
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
HeLa
IC50
> 200 μM
Compound: 6-MP
Antiproliferative activity against human HeLa cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
Antiproliferative activity against human HeLa cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
[PMID: 18467007]
HepG2
CC50
8 μM
Compound: 6MP
Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
[PMID: 21741130]
HepG2
IC50
8 μM
Compound: 6MP
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
[PMID: 17254669]
IGR-1
IC50
1.1 μg/mL
Compound: 6-MP
Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay
Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay
[PMID: 9358643]
IGR-1
IC50
12.3 μg/mL
Compound: 6-MP
Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay
Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay
[PMID: 9358643]
IGR-1
IC50
51.7 μg/mL
Compound: 6-MP
Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay
Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay
[PMID: 9358643]
J774
IC50
0.003 μM
Compound: 6-MP
Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method
Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method
[PMID: 10757708]
J774
IC50
0.5 μg/mL
Compound: 6-MP
Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay
[PMID: 9358643]
J774
IC50
3.6 μg/mL
Compound: 6-MP
Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay
[PMID: 9358643]
J774
IC50
61 μg/mL
Compound: 6-MP
Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay
Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay
[PMID: 9358643]
J774.A1
IC50
0.003 μM
Compound: 6-MP
Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay
Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay
[PMID: 16643040]
J774.A1
IC50
0.003 μM
Compound: 6-MP
Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay
Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay
[PMID: 16989528]
J774.A1
IC50
0.003 μM
Compound: 6-MP
Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay
Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay
[PMID: 18442289]
J774.A1
IC50
5.1 x 10-6 mg/mL
Compound: 6-mercaptopurine
Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay
Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay
[PMID: 19133758]
Jurkat
IC50
> 200 μM
Compound: 6-MP
Antiproliferative activity against human Jurkat cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
Antiproliferative activity against human Jurkat cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
[PMID: 18467007]
K562
IC50
0.4 μg/mL
Compound: 6-mercaptopurine
Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h
Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h
[PMID: 11844673]
K562
IC50
0.6 μg/mL
Compound: 6-MP
Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay
Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay
[PMID: 12617912]
K562
IC50
8.5 μg/mL
Compound: 6-mercaptopurine
Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h
Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h
[PMID: 11844673]
K562
IC50
> 10 μg/mL
Compound: 6-MP
Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay
Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay
[PMID: 12617912]
KB
ED50
0.1 μg/mL
Compound: 6-Mercaptopurine
Cytostatic activity against human KB cells assessed as growth inhibition after 72 hrs by colorimetric method
Cytostatic activity against human KB cells assessed as growth inhibition after 72 hrs by colorimetric method
[PMID: 671455]
KB
ED50
0.54 μg/mL
Compound: mercaptopurine
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
[PMID: 8277314]
KB
IC50
0.55 μg/mL
Compound: 6-MP
Cytotoxicity against human KB cells after 72 hrs by MTT assay
Cytotoxicity against human KB cells after 72 hrs by MTT assay
[PMID: 7807120]
L1210
IC50
0.02 μM
Compound: 6-MP
Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.
Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.
[PMID: 1906107]
L1210
IC50
0.024 μM
Compound: 6-MP
Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
[PMID: 1906107]
MCF7
CC50
3.2 μM
Compound: 6MP
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
[PMID: 21741130]
MCF7
IC50
1.4 μM
Compound: 6-mercaptopurine
Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
MCF7
IC50
1.4 μM
Compound: C2
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
MCF7
IC50
1.4 μM
Compound: C2
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
MCF7
IC50
2.79 μM
Compound: 6MP
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
[PMID: 23411915]
MCF7
IC50
3 μM
Compound: 6MP
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
[PMID: 17254669]
MCF7
IC50
5.8 μM
Compound: 6-mercaptopurine
Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay
Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
MCF7
IC50
5.8 μM
Compound: C2
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
MOLT-4
IC50
50.5 μM
Compound: 6-MP
Antiproliferative activity against human MOLT4 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
Antiproliferative activity against human MOLT4 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
[PMID: 18467007]
MT4
CC50
0.1 μM
Compound: 6MP
Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay
Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay
[PMID: 21741130]
MT4
IC50
0.1 μM
Compound: 6MP
Antiproliferative activity against human MT4 cells by MTT assay
Antiproliferative activity against human MT4 cells by MTT assay
[PMID: 17254669]
P388
ED50
0.25 μg/mL
Compound: mercaptopurine
Cytotoxicity against mouse doxorubicin-resistant P388 cells
Cytotoxicity against mouse doxorubicin-resistant P388 cells
[PMID: 8277314]
P388
ED50
0.7 μg/mL
Compound: mercaptopurine
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
[PMID: 8277314]
P388
IC50
0.26 μg/mL
Compound: 6-MP
Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay
Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay
[PMID: 7807120]
P388
IC50
0.3 μg/mL
Compound: 6-MP
Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay
[PMID: 9358643]
P388
IC50
0.7 μg/mL
Compound: 6-MP
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
[PMID: 7807120]
P388
IC50
2.1 μg/mL
Compound: 6-MP
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
[PMID: 9358643]
P388
IC50
37 μg/mL
Compound: 6-MP
Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay
[PMID: 9358643]
PANC-1
IC50
6.39 μM
Compound: 6-MP
Cytotoxicity against human PANC1 cells by crystal violet staining
Cytotoxicity against human PANC1 cells by crystal violet staining
[PMID: 20930123]
PBMC
IC50
149.5 nM
Compound: 6-MP
Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days
Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days
[PMID: 18467007]
PaTu 8988t
IC50
4.09 μM
Compound: 6-MP
Cytotoxicity against human Patu-T cells by crystal violet staining
Cytotoxicity against human Patu-T cells by crystal violet staining
[PMID: 20930123]
REH
IC50
2.94 μM
Compound: 6TP
Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay
Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay
[PMID: 30774864]
S49
EC50
8 μM
Compound: 6-MP
Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
[PMID: 221658]
S49
EC50
> 1000 μM
Compound: 6-MP
Cytotoxicity against HGPRTase-deficient mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
Cytotoxicity against HGPRTase-deficient mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
[PMID: 221658]
SK-MEL-28
CC50
15 μM
Compound: 6MP
Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay
Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay
[PMID: 21741130]
SK-MEL-28
IC50
15 μM
Compound: 6MP
Antiproliferative activity against human SK-MEL-28 cells by MTT assay
Antiproliferative activity against human SK-MEL-28 cells by MTT assay
[PMID: 17254669]
SK-MES-1
CC50
58 μM
Compound: 6MP
Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay
Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay
[PMID: 21741130]
SK-MES-1
IC50
58 μM
Compound: 6MP
Antiproliferative activity against human SKMES1 cells by MTT assay
Antiproliferative activity against human SKMES1 cells by MTT assay
[PMID: 17254669]
U-937
IC50
> 200 μM
Compound: 6-MP
Antiproliferative activity against human U937 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
Antiproliferative activity against human U937 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay
[PMID: 18467007]
Vero
IC50
118.6 μM
Compound: 6-mercaptopurine
Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
Vero
IC50
67.5 μM
Compound: 6-mercaptopurine
Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay
[PMID: 19711987]
Vero
IC50
67.6 μM
Compound: C2
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
Vero
IC50
67.6 μM
Compound: C2
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
Vero
IC50
> 117 μM
Compound: C2
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
WEHI-164
IC50
0.015 μM
Compound: 6-MP
Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay
Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay
[PMID: 16643040]
WEHI-164
IC50
0.015 μM
Compound: 6-MP
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay
[PMID: 16989528]
WEHI-164
IC50
0.015 μM
Compound: 6-MP
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay
[PMID: 18442289]
WEHI-164
IC50
0.017 μM
Compound: 6-MP
Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method
Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method
[PMID: 10757708]
WEHI-164
IC50
1.3 μg/mL
Compound: 6-MP
Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay
Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay
[PMID: 11087619]
WEHI-164
IC50
1.3 μg/mL
Compound: 6-MP
Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay
Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay
[PMID: 11430005]
WEHI-164
IC50
2.5 x 10-6 mg/mL
Compound: 6-mercaptopurine
Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay
Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay
[PMID: 19133758]
WEHI-164
IC50
2.7 μg/mL
Compound: 6-MP
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay
[PMID: 9358643]
WEHI-164
IC50
42 μg/mL
Compound: 6-MP
Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay
[PMID: 9358643]
WEHI-164
IC50
83 μg/mL
Compound: 6-MP
Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay
Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay
[PMID: 9358643]
WIL2-NS
CC50
3 μM
Compound: 6MP
Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay
Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay
[PMID: 21741130]
WIL2-NS
IC50
3 μM
Compound: 6MP
Antiproliferative activity against human WIL-2NS cells by MTT assay
Antiproliferative activity against human WIL-2NS cells by MTT assay
[PMID: 17254669]
体外研究(In Vitro)
6-Mercaptopurine hydrate (6-MP) 以剂量反应的方式诱导 NR4A3 转录活性增加 1.6 至 11 倍 (P<0.01)。研究发现，6-Mercaptopurine hydrate 会导致 NR4A3 蛋白水平剂量依赖性增加。与对照组相比，6-MP 治疗使基底细胞中的细胞表面 GLUT4 增加 1.8 至 3.6 倍 (P<0.01)，使胰岛素刺激细胞中的细胞表面 GLUT4 增加 2.9 至 4.4 倍 (P<0.01)。研究还发现，在基础和胰岛素刺激条件下，6-Mercaptopurine hydrate 以剂量反应的方式显著增加磷酸化 AS160[2]。
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
6-Mercaptopurine 相关抗体:
体内研究(In Vivo)
在 6-Mercaptopurine hydrate (6-MP) 治疗组的胎儿端脑中，S 期细胞群在治疗后 36 和 48 小时增加，并在 72 小时恢复到对照水平。G2/M 期细胞群在 24 小时开始增加，在 36 小时达到峰值，在 48 小时减少，最终在 72 小时恢复到对照水平。另一方面，亚 G1 期细胞群（凋亡细胞）在 36 小时开始增加，在 48 小时达到峰值，然后在 72 小时减少[3]。
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量
152.18
Formula
C5H4N4S
CAS 号
50-44-2
性状
固体
颜色
Light yellow to yellow
中文名称
巯嘌呤； 6-巯基嘌呤
结构分类
Others
初始来源
内源性代谢物
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, protect from light
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
细胞实验：
DMSO 中的溶解度 : 35.71 mg/mL (234.66 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)
配制储备液
浓度
溶剂体积
质量
1 mg
5 mg
10 mg
1 mM
6.5712 mL
32.8558 mL
65.7117 mL
5 mM
1.3142 mL
6.5712 mL
13.1423 mL
10 mM
0.6571 mL
3.2856 mL
6.5712 mL
查看完整储备液配制表
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。
摩尔计算器
稀释计算器
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
质量
kg
g
mg
μg
ng
pg
=
浓度
M
mM
μM
nM
pM
×
体积
L
mL
μL
×
分子量 *
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
浓度 (start)
M
mM
μM
nM
pM
C1
×
体积 (start)
L
mL
μL
V1
=
浓度 (final)
M
mM
μM
nM
pM
C2
×
体积 (final)
L
mL
μL
V2
动物实验：
请根据您的 实验动物和给药方式 选择适当的溶解方案。
以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.43 mM); 澄清溶液
此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案 二
请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (16.43 mM); 澄清溶液
此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案 三
请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (16.43 mM); 澄清溶液
此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；
如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一
请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 3.33 mg/mL (21.88 mM); 悬浊液; 超声助溶
扫码获得动物溶解方案
动物溶解方案计算器
请输入动物实验的基本信息：
给药剂量
mg/kg
动物的平均体重
g
每只动物的给药体积
μL
动物数量
只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO，
，均可在 MCE 网站选购。
，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 :
mg/mL
储备液配制方法 :
mg
药物溶于
μL
DMSO（母液浓度为 mg/mL）。
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
免费服务热线：400-820-3792
E-mail：sales@medchemexpress.cn
技术支持电话：021-58950656
技术支持邮箱：tech@medchemexpress.cn
动物实验体内工作液的配制方法 : 取
μL DMSO 储备液，加入
μL 。
μL ，混合均匀至澄清，再加
μL Tween 80，混合均匀至澄清，再加
μL 生理盐水。
将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料
纯度: 99.93%
选择批次：
HY-13677-57***
HY-13677-66****
HY-13677-09***
Data Sheet (647 KB)
SDS (644 KB)
COA (290 KB)
HNMR (246 KB)
LCMS (86 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Sahasranaman S, et al. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
[Content Brief]
[2]. Liu Q, et al. 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1081-92.
[Content Brief]
[3]. Kanemitsu H, et al. 6-Mercaptopurine (6-MP) induces cell cycle arrest and apoptosis of neural progenitor cells in the developing fetal rat brain. Neurotoxicol Teratol. 2009 Mar-Apr;31(2):104-9.
[Content Brief]